Figure 2: Oral glucose tolerance. | Scientific Reports

Figure 2: Oral glucose tolerance.

From: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Figure 2

(a) Plasma glucose concentrations over time, (b) area under glucose curve; AUCglucose, (c) plasma insulin concentrations over time, (d) area under insulin curve; AUCinsulin, and (e) insulinogenic index; AUCinsulin:glucose 0–30 mins in response to an oral glucose bolus (2 g/kg body weight) and (f) fasted plasma glucose-to-insulin ratio (t = 0 mins) in db/m (open) and db/db (grey) mice. Circles (ο) vehicle-treated; squares (◽) empagliflozin-treated; triangles (▵) metformin-treated; and diamonds (◊) empagliflozin + metformin co-treated. Data are means ± SEM (n = 6–11). *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, δP < 0.05 vs db/db metformin, ΨP < 0.05 vs all other db/db groups by one-way ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and trends denoted by dashed lines.

Back to article page